Cardiology

  • Aspirin for primary prevention
    Elise Henning, MD, MEd
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 458; DOI: https://doi.org/10.3949/ccjm.87c.08005
  • Should we monitor troponin up to peak value when evaluating for acute coronary syndrome?
    Nolan Anderson, MD, Samuel T. Ives, MD, Michelle D. Carlson, MD and Fred Apple, PhD, DABCC
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 480-482; DOI: https://doi.org/10.3949/ccjm.87a.18125

    No. Once troponin is over the 99th percentile, finding the peak value does not aid in diagnosis.

  • Cardiac troponin testing: Goodbye, ‘troponinemia’
    Anirudh Kumar, MD, Divyang R. Patel, MD and Venugopal Menon, MD
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 483-484; DOI: https://doi.org/10.3949/ccjm.87a.20013

    Any troponin elevation is prognostically important; dismissing it as “troponinemia” is no longer a viable strategy.

  • Does a short QT interval increase the risk of cardiac death in healthy people?
    Ahmed Subahi, MD, Ahmed S. Yassin, MD, Oluwole Adegbala, MD, Mohamed Shokr, MD and Luis Afonso, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 398-400; DOI: https://doi.org/10.3949/ccjm.87a.19090

    No, but it may warrant further investigation to determine if the patient is at risk.

  • The role of ISCHEMIA in stable ischemic heart disease
    Nikolaos Spilias, MD, Benjamin Zorach, MD, Kara Denby, MD and Stephen Ellis, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 401-409; DOI: https://doi.org/10.3949/ccjm.87a.20033

    Decisions regarding treatment of stable ischemic heart disease must remain individualized.

  • Stable coronary artery disease: Intervene or not?
    Vinayak Nagaraja, MBBS, MS, MMed (Clin Epi), FRACP and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 410-415; DOI: https://doi.org/10.3949/ccjm.87a.20048

    Stable coronary artery disease needs a patient-centered approach, and one size does not fit all.

  • Procedures and devices to treat resistant hypertension in chronic kidney disease
    Procedures and devices to treat resistant hypertension in chronic kidney disease
    Rama Dilip Gajulapalli, MD, Johnny Chahine, MD, Florian Rader, MD and Ashish Aneja, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 435-443; DOI: https://doi.org/10.3949/ccjm.87a.19099

    These treatments show potential. All but renal artery stenting are still experimental.

  • Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure
    George Thomas, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 444-447; DOI: https://doi.org/10.3949/ccjm.87a.20092

    Device-based therapies have shown promise, but many points still need clarification.

  • Familial hypercholesterolemia: Clarifications
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 320; DOI: https://doi.org/10.3949/ccjm.87c.06001

    Comments on xanthoma vs xanthelasmas, and goal LDL-C.

  • Medical complications of anorexia nervosa
    Jeana Cost, LPC,CEDS, Mori J. Krantz, MD and Philip S. Mehler, MD,FACP,FAED
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 361-366; DOI: https://doi.org/10.3949/ccjm.87a.19084

    Many of these complications resolve with treatment and weight gain, but others can lead to permanent damage.

Pages